Recombinant protein within human Apolipoprotein CIII aa 1-99.
Species Reactivity
Human
Validated Applications
WB, IHC-P
Target Molecular Weight
Predicted band size: 11 kDa
Positive Control
Human plasma.
Conjugation
unconjugated
Clone Number
PSH24-47
Reactivity Data
Tested
Verified (internally validated)
Published
Reported in literature (not internally validated)
Predicted
Predicted reactive (based on sequence homology)
Not recommended
Not recommended (failed internal validation)
WB
IHC-P
human
mouse
rat
Product Features
Form
Liquid
Concentration
1 mg/mL.(The concentration of this product may be batch-dependent)
Lot Concentration Lookup
Storage Instructions
Store at 2-8℃. Avoid freeze.
Storage Buffer
PBS (pH7.4).
Isotype
IgG
Purification Method
Protein A affinity purified.
Application Dilution
Target
Function
Apolipoprotein C-III also known as apo-CIII, and apolipoprotein C3, is a protein that in humans is encoded by the APOC3 gene. Apo-CIII is secreted by the liver as well as the small intestine, and is found on triglyceride-rich lipoproteins such as chylomicrons, very low density lipoprotein (VLDL), and remnant cholesterol. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to inhibit hepatic uptake of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia. Recent evidence suggests an intracellular role for Apo-CIII in promoting the assembly and secretion of triglyceride-rich VLDL particles from hepatic cells under lipid-rich conditions. However, two naturally occurring point mutations in human apoC3 coding sequence, namely Ala23Thr and Lys58Glu have been shown to abolish the intracellular assembly and secretion of triglyceride-rich VLDL particles from hepatic cells.
Background References
1. Naber A et al. Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids. Int J Mol Sci. 2023 Oct
2. Naber A et al. Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes. Int J Mol Sci. 2024 May
This data was developed using HA724449, the same antibody clone in a different buffer formulation. Western blot analysis of Apolipoprotein CIII on human plasma lysate with Rabbit anti-Apolipoprotein CIII antibody (HA724449) at 1/5,000 dilution.
Lysates/proteins at 30 µg/Lane.
Exposure time: 20 seconds; ECL: K1801
Blocking: 5% NFDM/TBST, 1 hour at room temperature
Primary antibody: HA724449, 1/5,000 in primary antibody dilution buffer (K1803), overnight at 4 °C
Secondary antibody: Goat anti-Rabbit IgG-HRP (HA1001), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature
Predicted band size: 11 kDa
Observed band size: 10-15 kDa
This data was developed using HA724449, the same antibody clone in a different buffer formulation. Application: Immunohistochemistry (IHC-P)
Species: Human
Tissue: Liver
Sample: Paraffin-embedded section